mAbxience Signs Licensing Deal with Abiogen Pharma 

• mAbxience has signed a licensing agreement with Abiogen Pharma to commercialise a biosimilar in Italy.

• mAbxience will retain marketing authorisation, while Abiogen will manage all commercial operations.

mAbxience, a Fresenius Kabi majority-owned CDMO with additional ownership from Insud Pharma, has entered a strategic licensing agreement with Italy-based Abiogen Pharma to develop and commercialise a biosimilar product in the Italian market.

Under the terms of the agreement, mAbxience will hold the marketing authorisation for the biosimilar candidate. Abiogen Pharma will be responsible for all commercialisation and marketing activities within Italy. The partnership brings together mAbxience’s biosimilar development capabilities with Abiogen’s established commercial infrastructure.

The agreement strengthens both firms’ positions in the growing biologics sector. “We are thrilled to partner with Abiogen Pharma to bring this biosimilar candidate to patients in Italy,” said José Ramón Millán, Global Partnering & Portfolio Director at mAbxience.

The collaboration aligns with both companies’ long-term strategies to improve access to biologic medicines and manage healthcare costs. Abiogen’s Chief Commercial Officer Prisca Di Martino said the agreement is part of a strategic plan to focus on therapeutic areas where the company has deep expertise.